BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 38446476)

  • 1. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 2. Epcoritamab in B-cell malignancies: current status and prospects.
    Molica S; Rossi M; Allsup D
    Expert Opin Biol Ther; 2024; 24(1-2):1-5. PubMed ID: 38343083
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
    Mhibik M; Gaglione EM; Eik D; Herrick J; Le J; Ahn IE; Chiu C; Wielgos-Bonvallet M; Hiemstra IH; Breij ECW; Chen J; Reilly EB; Epling-Burnette PK; Szafer-Glusman E; Sun C; Wiestner A
    Blood Adv; 2023 Aug; 7(15):4089-4101. PubMed ID: 37219524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epcoritamab, a promising therapy for Richter syndrome?
    Kater A
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):90-91. PubMed ID: 38446476
    [No Abstract]   [Full Text] [Related]  

  • 5. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
    Jamroziak K; Tadmor T; Robak T; Polliack A
    Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Richter transformation in the era of novel agents.
    Ding W
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):256-263. PubMed ID: 30504319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
    Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
    J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.